Hemoglobin >= . g/dL and no known active bleeding, measured within  days prior to administration of study treatment
Within  days of the first dose of study drug: Hemoglobin >= . g/dL
Hemoglobin >=  g/dL without transfusion within  week preceding study drug administration.
Hemoglobin >=  g/dL results within  days before study drug administration
Hemoglobin >= . g/dL with no blood transfusion in the past  days, measured within  days prior to administration of study treatment
Hemoglobin >=  g/dL without transfusion within  week preceding study drug administration
Hemoglobin >=  g/dL without transfusion within  week preceding study drug administration
Hemoglobin >=  g/dL without transfusion within  week preceding study drug administration
Within  days of first dose of study drug administration: Hemoglobin >= .g/dl
Within  days prior to administration of study treatment: Hemoglobin ? . g/dL with no blood transfusion in the past  days
Within  days of first dose of study drug: Hemoglobin >=  g/dL
Within  days prior to first dose of study drug treatment: Hemoglobin >=  g/dL without transfusion in the previous week
Measured within  days prior to administration of study treatment: Hemoglobin >= . g/dL with no blood transfusion in the past  days
Within  days prior to administration of therapy: Hemoglobin >=  g/dL with no blood transfusion within  days of initiation of therapy
Hemoglobin >= . g/dL, measured within  days prior to administration of study treatment
Patients must have adequate organ and marrow function measured within  days prior to administration of ABT- as defined below:\r\n* >= . g/dL hemoglobin (Hb) with no blood transfusion in the past  days
Within  weeks of administration of study therapy: Hemoglobin >=  g/dL
Measured within  days prior to administration of ABT-: >= . g/dL hemoglobin (Hb) with no blood transfusion in the past  days
Hemoglobin >=  g/dL without transfusion within  week preceding study drug administration
Measured within  days prior to administration of study treatment: Hemoglobin >= . g/dL
